|Awarded On||November 02, 2011|
|Title||Engineering and Preliminary Evaluation of a Fully Human, Non-Immunogenic Asparaginase For the Treatment of L-Asn Auxotrophic Cancers|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||George Georgiou|
|Cancer Sites||Leukemia, Ovary, Pancreas|
Many cancers have genetic defects that lead them to lose the ability to synthesize certain amino acids. Unlike non-malignant cells the cancer cells have to take up these amino acids from the blood supply. Drug treatments that lead to depletion of the required amino acid from the blood supply starve the tumor leading to cancer cell killing while non-malignant cells that can synthesize that amino acid are unaffected. The most effective way to deplete a specific amino acid in the blood supply is by injection of an enzyme that selectively destroys it. This approach has proven to be highly efficacious in the treatment of leukemias and other tumors that cannot synthesize the amino acid L-Asparagi...